Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage
The first stage of this trial required a minimum of two responses out of ten patients to move to the second stage of the trial, which is now enrolling.
- The first stage of this trial required a minimum of two responses out of ten patients to move to the second stage of the trial, which is now enrolling.
- Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis.
- Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors.
- NeoTX is responsible for the global development and commercialization of naptumomab for the treatment of cancer under the license agreement.